Recently Featured

FDA Grants Breakthrough Status to Generative AI Chatbot for Surgical Patients

March 10, 2026
The Food and Drug Administration (FDA) has granted breakthrough device designation to a generative AI chatbot designed for patients recovering from joint replacement surgery. This marks a significant step in the FDA’s evolving stance on artificial intelligence in healthcare, particularly as it seeks to establish a regulatory framework for AI technologies. The designation comes at…

Researchers Advance Human Embryo Models, Sparking Ethical Dilemmas

March 10, 2026
Researchers are racing to engineer highly realistic human embryo models using stem cells in the lab. Some of the newest models are now so similar to real human embryos that it’s unsettling even if also exciting in terms of research potential. One core goal for embryo modeling is to better understand early human development and…

Ascendis Secures FDA Approval for Yuviwel, a New Treatment for Dwarfism

March 10, 2026
Ascendis Pharma has received FDA approval for Yuviwel, a once-weekly injection aimed at treating achondroplasia, a common form of dwarfism. This approval marks a significant milestone for Ascendis, positioning Yuviwel as a direct competitor to BioMarin’s established daily treatment, Voxzogo, which has dominated the market since its launch. The entrance of Yuviwel into the market…

CMS Halts Enrollment in Elevance’s Medicare Advantage Plans Due to Misconduct

March 10, 2026
Elevance Health will no longer be able to enroll individuals into its Medicare Advantage plans starting March 31, following a suspension notice from the Centers for Medicare and Medicaid Services (CMS) that cites years of regulatory noncompliance. This suspension is a direct consequence of Elevance’s failure to provide required information to federal regulators over a…

Ongoing Cases